Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high <i>in vivo</i> efficacy

Abstract

led to the reduction of bacterial loads (cfu, colony-forming units) in muscle, lung and kidneys by five orders of magnitude compared to vehicle-treated mice. These findings qualify cystobactamids as highly promising lead structures against infections caused by Gram-positive and Gram-negative bacterial pathogens.